SC Plaque psoriasis Adult & patient who are anti-TNF-α inadequate responders 300 mg w/ initial dose at wk 0, 1, 2, 3 & 4 followed by mthly maintenance dose given as 2 SC inj of 150 mg. Patient ≥90 kg may derive additional benefit from 300 mg every 2 wk.
Ped ≥50 kg 150 mg, may be increased to 300 mg in some patients,
25 to <50 kg 75 mg, may be increased to 150 mg in some patients,
<25 kg 75 mg. Each 75 & 150 mg dose is given as single dose. Each 300 mg dose is given as 2 SC inj of 150 mg.
Psoriatic arthritis, axial spondyloarthritis, ankylosing spondylitis 150 mg w/ initial dose at wk 0, 1, 2, 3 & 4 followed by mthly maintenance dose, may be increased to 300 mg in 2 divided doses.
Patient w/ concomitant moderate to severe plaque psoriasis Follow adult plaque psoriasis dosage & administration.
Non-radiographic axial spondyloarthritis 150 mg w/ initial dose at wk 0, 1, 2, 3 & 4 followed by mthly maintenance dose.
Enthesitis-related arthritis & juvenile psoriatic arthritis Patients ≥50 kg 150 mg at wk 0, 1, 2, 3 & 4 followed by mthly maintenance dose given as single dose,
<50 kg 75 mg at wk 0, 1, 2, 3 & 4 followed by mthly maintenance dose given as single dose.
Sign Out
